Novo Nordisk

News

Novo Nordisk once-weekly insulin clears first phase 3 test

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying to change that.

R&D

Big pharma vs small diseases: Tackling rare diseases

Rare diseases aren’t as rare as the appellation suggests.

News

Lilly fires a broadside at Novo Nordisk's obesity ambitions

Denmark's Novo Nordisk has been almost single-handedly rebuilding the market for drugs to treat obesity over the last few years with its GLP-1 agonist drugs

R&D

No room for commercial competition in sustainable pharma

With the healthcare sector accounting for around 4% of global emissions – about the same as a small country – only an ecosystem-wide effort will succeed.

Views & Analysis

IWD: Spotlight on women in life sciences

To celebrate International Women's Day, we speak to design engineer at Envair Technology Darina Shopova; general manager, UK & ROI at Healthcare Business of Merck Doina Ionescu; and vic

News

Novo Nordisk eyes obesity sales of $3.7bn in 2025 thanks to ...

Novo Nordisk's rollout of obesity therapy Wegovy has been beset by production problems, but the company says these are being resolved and it now anticipates it will help drive obesity sales

Novo Nordisk once-weekly insulin clears first phase 3 test

Big pharma vs small diseases: Tackling rare diseases

Lilly fires a broadside at Novo Nordisk's obesity ambitions

No room for commercial competition in sustainable pharma

IWD: Spotlight on women in life sciences

Novo Nordisk eyes obesity sales of $3.7bn in 2025 thanks to ...

Dexcom is first to join FDA/CMS health tech pilot

Discover a new era of healthcare panel engagement: Grounded ...

Novo Nordisk

Editor's Picks